→ Company → History
History
Protox is dedicated to research and development to become a company
that produces the world’s highest quality botulinum toxin products.
2020 ~ 2023
Growth of Technology
2023
Approved for Clinical trial Phase 3(IND) by Minzdrav(Russia)
Submission of NDA in Korea
Attracting 4billion KRW in investment from China
Cosmoprof Worldwide Bologna- Exhibitor Initiation of Clinical trial Phase 3
Submission of NDA in Korea
Attracting 4billion KRW in investment from China
Cosmoprof Worldwide Bologna- Exhibitor Initiation of Clinical trial Phase 3
2022
CPhI south east asia 2022 – Exhibitor
Approved for Clinical trial Phase 3(IND) by MFDS
Approved for Clinical trial Phase 3(IND) by MFDS
2021
Submission of Clinical trial Phase 3 application to MFDS
Completion of Clinical trial Phase 1/2
Initiation of Clinical trial Phase 2
Completion of Clinical trial Phase 1
Completion of Clinical trial Phase 1/2
Initiation of Clinical trial Phase 2
Completion of Clinical trial Phase 1
2020
Initiation of Clinical trial Phase 1
Approved for Export Authorization
Approved for GMP and Clinical trial Phase 1/2(IND) by MFDS
Submission of clinical trial application to MFDS
Completion of clinical trial sample production
Approved for Export Authorization
Approved for GMP and Clinical trial Phase 1/2(IND) by MFDS
Submission of clinical trial application to MFDS
Completion of clinical trial sample production
2019
Completion of Non-clinical study
Approved for drug manufacturing by MFDS
CPhI China 2019 – Exhibitor
Completion of Plant
Start Non-clinical study(Feb. 15)
Completion of non-clinical trial sample production
Approved for drug manufacturing by MFDS
CPhI China 2019 – Exhibitor
Completion of Plant
Start Non-clinical study(Feb. 15)
Completion of non-clinical trial sample production
2018
Process development for Non-clinical trial product
Characterization of Botulinum Toxin
Contracted with Non-Clinical Trial CRO
Characterization of Botulinum Toxin
Contracted with Non-Clinical Trial CRO
2018 ~ 2019
Foundation for Growth
2015 ~ 2017
Inception
2017
Biological Agent manufacturing report
by Ministry of Trade, Industry and Energy
(Registration No. : Biotech and Nanotech Division 17-11)
Animal experimental facilities registration
Botulinum movement and retention report
by Korea Centers for Disease Control and
Prevention (Management No. : 4-026-CBB-CO-040)
Completed reporting of high-risk pathogen treatment research facility (No. KCDC-17-2-01)
by Ministry of Trade, Industry and Energy
(Registration No. : Biotech and Nanotech Division 17-11)
Animal experimental facilities registration
Botulinum movement and retention report
by Korea Centers for Disease Control and
Prevention (Management No. : 4-026-CBB-CO-040)
Completed reporting of high-risk pathogen treatment research facility (No. KCDC-17-2-01)
2016
Extension of expansion of Reasearch Institute
(in Hyangnam-eup, Hwaseong-si, Gyeonggi-do)
Took over MEDICA Korea Co., Ltd. (USD 33million)
(in Hyangnam-eup, Hwaseong-si, Gyeonggi-do)
Took over MEDICA Korea Co., Ltd. (USD 33million)
2015
Authorized venture company
By Korea Technology Finance Corporation
Established PROTOX Inc.
By Korea Technology Finance Corporation
Established PROTOX Inc.
